Nvidia just gave drug discovery its ChatGPT moment. At the BIO International Convention on June 23, the chipmaker unveiled its BioNeMo Agent Toolkit, a comprehensive suite that lets AI agents autonomously handle complex scientific workflows across biology, chemistry, genomics, and pharmaceutical development. Certara, a scientific data and workflow platform, is among the first wave of companies integrating the toolkit into its operations.
What the BioNeMo toolkit actually does
The toolkit packages over a decade’s worth of Nvidia’s life sciences libraries, open models, and specialized tools into a format where biomolecular models become “callable skills.” Instead of a scientist manually running protein structure predictions, virtual screening, molecular docking, and generative chemistry workflows, an AI agent can chain these tasks together autonomously.
Certara’s integration means the company can connect its existing scientific data systems with these AI capabilities, potentially compressing research timelines that have historically stretched across years and consumed enormous budgets.
The scale of what’s at stake
